Absorption and presynaptic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in health males

Pharmaceutical Research

Volumn 13, Issue 10, 1996, Pages 1535-1540

  Barrett, Jeffrey S ^a   Szego, Peter ^b   Rohatagi, Shashank ^a   Morales, Richard J ^a   DeWitt, Kimberly E ^a   Rajewski, Gregory ^b   Ireland, Joyce ^b  

^a Somerset Pharmaceutical   (United States)

^b MDS Inc   (Canada)

Author keywords

Pharmacokinetics; Selegiline; Site specific

Indexed keywords

SELEGILINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; DESMETHYLSELEGILINE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG METABOLISM; GASTROINTESTINAL TRACT; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; SORE THROAT; STOMACH ABSORPTION; COMPARATIVE STUDY; DUODENUM; ILEUM; INTESTINE; JEJUNUM; METABOLISM; STOMACH;

ADMINISTRATION, ORAL; ADULT; AMPHETAMINE; AMPHETAMINES; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DUODENUM; HUMANS; ILEUM; INTESTINAL ABSORPTION; INTESTINES; JEJUNUM; MALE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; STOMACH;

EID: 0029658081     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016035730754     Document Type: Article

References (19)

1. E. H. Heinonen, M. Anttila, H. Karnani, R. Lammintausta. Mov. Disord. 9(Suppl. 1):P248 (1994).
2. T. Yoshida, T. Oguro, and Y. Kuroiwa. Xenobiotica 17(8):957-963 (1987).
3. L. Yamlahi, J. G. Besner, and G. Caille. Pharm. Res. 10(10), Suppl:S336 (1993).
4. J. S. Barrett, S. Rohatagi, K. E. DeWitt, R. J. Morales, and A. R. DiSanto. Am. J. Ther. 3:298-313 (1996).
5. S. Rohatagi, J. S. Barrett, K. E. DeWitt, and R. J. Morales. Biopharm. Drug Dispos. (in press).
6. J. Gaudreault, S. Wang, and R. Lalonde. Pharm. Res. 12(9, Suppl):S-327 (1995).
7. J. S. Barrett, S. Rohatagi, K. E. DeWitt, and R. M. Morales. Clin. Pharm. Ther. 59(2):PIII-75,206 (1996).
8. P. J. Sinko, N. R. Patel, and P. Hu. Int. J. Pharm. 109:125-133 (1994).
9. P. E. Warner, K. L. R. Brouwer, E. K. Hussey, G. E. Dukes, W. D. Heizer, K. H. Donn, I. M. Davis, and J. R. Powell. Pharm. Res. 12(1):138-143 (1995).
10. P. H. Marathe, D. E. Salazar, D. S. Greene, J. Brennan, U. A. Shukla, R. H. Barbhaiya. Pharm. Res. 12(11):1716-1721 (1996).
11. K. K. H. Chan, A. Buch, R. D. Glazer, V. A. John, and W. H. Barr. Pharm. Res. 11(3):432-437 (1994).
12. J. M. Grace, M. T. Kinter, and T. L. Macdonald. Chem. Res. Toxicol. 7(3):286-290 (1994).
13. D. R. Krishna and U. Klotz. Clin. Pharmacokinet. 26(2):144-160 (1994).
14. K. F. Ilet, L. B. G. Tee, P. T. Reeves, and R. F. Minchin. Pharmac. Ther. 46:67-93 (1990).
15. D. Lessard, F. Beaudry, and A. Niggebrugge. Pharm. Res. 11(10, Suppl):S-17 (1994).
16. SAS Institute, Cary, North Carolina
17. FDA Division of Bioequivalence. Guidance: Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design. July 1, 1992.
18. I. Mahmood, J. S. Marinac, S. Willsie, and W. D. Mason. Biopharm. Drug Dispos. 16:535-545 (1995).
19. E. H. Heinonen, M. I. Anttila, and R. A. S. Lammintausta. Clin. Pharmacol. Ther. 56:742-749 (1994).